Nvidia Partners With Quantum-Si To Advance Single-Molecule Analysis

On Wednesday, Quantum-Si Incorporated QSI stock traded over 100% higher after the protein sequencing company announced a collaboration with NVIDIA Corporation NVDA to develop its new proteomics platform, Proteus, and advance Quantum-Si’s core technologies of amino acid binders and aminopeptidases using NVIDIA AI and accelerated computing.

This collaboration aims to significantly enhance data processing speeds to handle the increased data volume from Proteus.

“We are thrilled to collaborate with NVIDIA to make single-molecule proteomics more accessible to researchers,” said John Vieceli, Ph.D., chief product officer of Quantum-Si. We have been leveraging AI protein structure prediction tools with NVIDIA BioNeMo, both in the cloud and on-premises to design new and improved biomolecules.”

Concurrently, Quantum-Si and SkyWaterTechnology will jointly expand their relationship to support the development of Proteus.

The expanded collaboration will develop the consumable for Proteus, enabling simultaneous large-factor protein sequencing.

Quantum-Si and SkyWater began partnering in 2021 on the first-generation Platinum platform and announced the transition to support production in the second quarter of 2024.

SkyWater will continue to supply the consumables for the Platinum Pro product as the two companies expand their engagement to support the commercialization of Proteus.

Quantum-Si also partnered with Planet Innovation to develop and manufacture Proteus.

Currently, Planet Innovation is the contract manufacturer for Quantum-Si’s Platinum Pro instrument, which will debut in the first half of 2025.

On Wednesday, Quantum-Si announced a distribution agreement with Avantor Inc AVTR.

Through this collaboration, Avantor will distribute Quantum-Si’s Next-Generation Protein Sequencing (NGPS) portfolio to researchers across all market segments in the U.S. and Canada.

The distribution agreement enables Avantor to offer Quantum-Si’s protein sequencing technology to a broad range of laboratories focused on proteomics.

Quantum-Si’s platform leverages single-molecule sequencing technology, with applications across protein and biomarker identification, antibody characterization, protein barcoding, and post-translational modification analysis to deliver insights into protein structure and function.

Price Action: QSI stock is up 119% at $1.39 during the premarket session at last check Wednesday.

Read Next:

• Exxon Mobil’s Lithium Leap: 100,000 Metric Tons To Fuel LG Chem’s US Plant

Photo: Gorodenkoff/Shutterstock.com